• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Bon Natural Life Limited

    4/11/25 7:05:30 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

    Commission File Number 001-40517

     

    BON NATURAL LIFE LIMITED

    (Translation of registrant’s name into English)

     

    Room 601, Block C, Gazelle Valley, No.69, Jinye Road

    High-Tech Zone, Xi’an, Shaanxi, China

    People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

     

    Supply Agreement

     

    On February 19, 2025, our subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd (“App-Chem”) entered into a Supply Agreement (the “Agreement”) with Shanghai Yunsheng International Trading Co., Ltd. (“Shanghai Yunsheng”). Under the Agreement, App-Chem agreed to supply Shanghai Yunsheng with apple polyphenol health products, including (i) apple polyphenol for plant-based beverages; (ii) apple polyphenol plant-based protein powder beverage, and (iii) apple polyphenol tablet candy, which Shanghai Yunsheng will sell and distribute. The term of the Agreement is twenty-four (24) months.

     

    App-Chem will be responsible for quality control such that all of its products are compliant with applicable national standards, and provide a Certification of Analysis (COA). App-Chem will also provide adequate transportation insurance.

     

    Any quality claims from Shanghai Yunsheng must be submitted within two (2) months from the date on which they received the products. App-Chem is not liable for any quality issues arising from improper storage or contamination during unpacking or handling by Shanghai Yunsheng. If any quality discrepancy arises, a re-inspection shall be conducted by a mutually agreed-upon third-party. If the re-inspection confirms non-conformity, App-Chem shall bear all costs incurred.

     

    App-Chem must receive full advanced payment from Shanghai Yunsheng for any products before such products are dispatched.

     

    Either party that terminates the Agreement without justifiable reasons (as defined in the Agreement) or fails to fulfill its obligations under the Agreement shall compensate the other party with a liquidated damages equivalent to 20% of the total Agreement amount. Any lawsuits must be filed in a court located in the People’s Republic of China.

     

    The foregoing is a summary of the material terms of the Agreement. The Agreement contains additional terms, covenants and conditions and should be reviewed in its entirety for additional information.

     

    Exhibits

     

    The following exhibits are included in this Form 6-K:

     

    Exhibit No.   Description of Exhibit

    10.1

     

    Translation of Supply Agreement with Shanghai Yunsheng International Trading Co., Ltd.

    99.1   Press Release dated April 11, 2025

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: April 11, 2025 Bon Natural Life Limited
         
      By: /s/ Yongwei Hu
        Yongwei Hu
        Chairman and Chief Executive Officer

     

     

    Get the next $BON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade

      XI'AN, China, May 22, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a leading functional ingredient distributor in China. The term of the Agreement is 24 months with a total contract value of US$ 24 million. Pursuant to the agreement, Shanghai Risesun will market, distribute and sell BON's tea pigment series health products in China. Leveraging a robust biological profile that includes lipid modulation, glycemic control, antioxidant activity,

      5/22/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

      XI'AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner of BON's postbiotic hypoglycemic ingredients. BON aims to expand into the global blood sugar health market through the development of a series of innovative hypoglyc

      5/16/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split

      XI'AN, China, May 15, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that it will effect a 1-for-25 reverse stock split ("Reverse Stock Split") of its authorized, issued and outstanding Class A ordinary shares, par value $0.001 per share. The Reverse Stock Split will become effective at 12:01a.m., Eastern Time, on May 19, 2025. At such time, each 25 issued and outstanding Class A ordinary shares will automatically be reclassified into one new Class A ordinary share. Proportional adjustments will be made to outstanding equity aw

      5/15/25 6:15:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Financials

    Live finance-specific insights

    See more

    $BON
    SEC Filings

    See more
    • Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

      Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

      2/7/23 8:30:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

      7/28/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

      1/28/22 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/22/25 3:16:58 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/16/25 9:05:19 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      4/23/25 12:25:36 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation
    • Bon Natural Life Limited Announces Change to Board Composition

      XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

      6/30/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care